Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
Status:
Terminated
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Phase II, multi-centric, open-label, study.
Disseminated diffuse large B-cell lymphoma in patients older than 60: evaluation of
fractionated radio-immunotherapy with 90Y-DOTA-hLL2 as a consolidation therapy after first
line of chemotherapy.